The MINDACT clinical trial confirmed the prognostic ability of MammaPrint gene signature for patients with invasive early-stage BC, irrespective of their ER and PR expression, HER2-status, and lymph nodal involvement [12]. This evidence concerns the gene PGR and breast cancer.